Personalized pharmacogenomics: Predicting efficacy and adverse drug reactions

Annual Review of Genomics and Human Genetics

Volumn 15, Issue , 2014, Pages 349-370

  Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

biomarkers; drug efficacy; drug safety; personalized medicine; pharmacogenomics

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIOPURINE METHYLTRANSFERASE; PHARMACOLOGICAL BIOMARKER;

DRUG EFFICACY; DRUG SAFETY; GENE; GENETIC ASSOCIATION; HEPATITIS C; HEREDITY; HUMAN; MYOPATHY; NEOPLASM; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; REVIEW; SEQUENCE ANALYSIS; THROMBOCYTE FUNCTION; ADVERSE DRUG REACTION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN GENOME; PATHOLOGY; PROGNOSIS;

BIOMARKERS, PHARMACOLOGICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE-ENVIRONMENT INTERACTION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; PROGNOSIS;

EID: 84906855893     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-090413-025419     Document Type: Review

References (134)

1. Acad. Med. Sci. 2013. Realising the Potential of Stratified Medicine. London: Acad. Med. Sci.
2. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, et al. 2011. Hepatitis C pharmaco-genetics: state of the art in 2010. Hepatology 53:336-45
3. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, et al. 2013. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58:777-87
4. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, et al. 1980. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 315:1107-9
5. Behr ER, Roden D. 2013. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur. Heart J. 34:89-95
6. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. 2012. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu. Rev. Pharmacol. Toxicol. 52:401-31
7. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, et al. 2011. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12:233-37
8. Cappellini MD, Fiorelli G. 2008. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64-74
9. Carr DF, Chaponda M, Jorgensen AL, Castro EC, van Oosterhout JJ, et al. 2013. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin. Infect. Dis. 56:1330-39
10. Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, et al. 2013. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94:695-701
11. Cary KC, Cooperberg MR. 2013. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther. Adv. Urol. 5:318-29
12. *3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19:139-46
13. *1502 screening in Taiwan. N. Engl. J. Med. 364:1126-33
14. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, et al. 2004. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486
15. Connor S. 2003. Glaxo chief: Our drugs do not work on most patients. Independent, Dec. 8. http://www.independent.co.uk/news/science/glaxo-chief-our- drugs-do-not-work-on-most-patients-575942.html
16. Daly AK. 2010. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11:241-46
17. Daly AK. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52:21-35
18. *5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41:816-19
19. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. 2013. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am. Heart J. 165:1008-14
20. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. 2009. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 4:e4439
21. Dawson SJ, Rueda OM, Aparicio S, Caldas C. 2013. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 32:617-28
22. Ding WY, Lee CK, Choon SE. 2010. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int. J. Dermatol. 49:834-41
23. Donnan JR, Ungar WJ, Mathews M, Rahman P. 2011. Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Ther. Drug Monit. 33:192-99
24. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, et al. 2011. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 89:210-16
25. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, et al. 2014. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet. 53:271-82
26. Drazen JM, Silverman EK, Lee TH. 2000. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56:1054-70
27. Druker BJ. 2002. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur. J. Cancer. 38(Suppl. 5):S70-76
28. Edwards SG, Hubbard V, Aylett S, Wren D. 1999. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad. Med. J. 75:680-81
29. Evans DA. 1968. Genetic variations in the acetylation of isoniazid and other drugs. Ann. N.Y. Acad. Sci. 151:723-33
30. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. 2011. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57:612-18
31. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367:1694-703
32. Fugger L, McVean G, Bell JI. 2012. Genomewide association studies and common disease-realizing clinical utility. N. Engl. J. Med. 367:2370-71
33. Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, et al. 2012. Adverse drug reactions causing admission to a paediatric hospital. PLoS ONE 7:e50127
34. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
35. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. 2013. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341:295-98
36. Harbour R, Miller J. 2001. A new system for grading recommendations in evidence based guidelines. BMJ 323:334-36
37. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, et al. 1999. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117:1181-86
38. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, et al. 2002. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-22
39. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, et al. 2013. A catalog of published genome-wide association studies. Accessed Dec. 6. Natl. Hum. Genome Res. Inst., Bethesda, MD.
40. http://www.genome.gov/gwastudies
41. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, et al. 2008. Ticlopidine-induced hepa-totoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8:29-33
42. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, et al. 2012. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e152S-84S
43. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. 2009. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS ONE 4:e7960
44. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, et al. 2007. Which drugs cause preventable admissions to hospital? A systematic review. Br. J. Clin. Pharmacol. 63:136-47
45. Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK. 2009. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics 10:225-33
46. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, et al. 2004. Associationof genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5:203-11
47. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, et al. 2006. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16:297-306
48. *5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102:4134-39
49. Ingelman-Sundberg M. 2004. Pharmacogenetics of cytochrome P450and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25:193-200
50. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, et al. 2010. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28:4674-82
51. Int. Warfarin Pharmacogenet. Consort. 2009. Estimation of the warfarin dose with clinical and phar-macogenetic data. N. Engl. J. Med. 360:753-64
52. Ioannidis JP. 2013. To replicate or not to replicate: the case of pharmacogenetic studies: Have phar-macogenomics failed, or do they just need larger-scale evidence and more replication? Circ. Cardiovasc. Genet. 6:413-18
53. Jonas DE, McLeod HL. 2009. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30:375-86
54. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. 2012. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS ONE 7: e44064
55. Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, et al. 2013. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3:e223
56. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, et al. 2008. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9:1617-22
57. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, et al. 2013. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369:2283-93
58. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, et al. 2007. Genome-wide pharmaco-genetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8:186-195
59. Kittaneh M, Montero AJ, Gluck S. 2013. Molecular profiling for breast cancer: a comprehensive review. Biomark. Cancer 5:61-70
60. Kornbluth A, Sachar DB. 2010. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 105:501-23
61. Lai M, Afdhal NH. 2012. Clinical utility ofinterleukin-28B testing in patients with genotype 1. Hepatology 56:367-72
62. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-5
63. Lennard L, Van Loon JA, Weinshilboum RM. 1989. Pharmacogenetics of acute azathioprine toxic-ity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46:149-54
64. Lesko LJ. 2008. The critical path of warfarin dosing: finding an optimal dosing strategy using pharma-cogenetics. Clin. Pharmacol. Ther. 84:301-3
65. Liu M, Wang L, Bongartz T, Hawse JR, Markovic SN, et al. 2012. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res. 14:R41
66. *1502 allele in Thai population. Epilepsia 49:2087-91
67. Lupberger J, Felmlee DJ, Baumert TF. 2013. Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Hepatology 58:439-41
68. Luzzatto L. 2010. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 376:739-41
69. Madian AG, Wheeler HE, Jones RB, Dolan ME. 2012. Relating human genetic variation to variation in drug responses. Trends Genet. 28:487-95
70. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor aba-cavir. Lancet 359:727-32
71. *5701 screening for hyper-sensitivity to abacavir. N. Engl. J. Med. 358:568-79
72. *11:01 in anti- hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 64:1233-37
73. *1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48:1015-18
74. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, et al. 2013. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502:377-80
75. *3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364:1134-43
76. McLeod HL. 2013. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339:1563-66
77. *1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75:579-82
78. Meyer UA. 2004. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5:669-76
79. Meyer UA, Zanger UM, Schwab M. 2013. Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53:475-502
80. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. 2007. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104:13513-18
81. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, et al. 2013. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet. Genomics 23:383-94
82. Moyer VA, US Prev. Serv. Task Force. 2012. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157:120-34
83. Nebert DW, Zhang G, Vesell ES. 2013. Genetic risk prediction: individualized variabilityinsusceptibility to toxicants. Annu. Rev. Pharmacol. Toxicol. 53:355-75
84. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, et al. 2000. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47:717-20
85. *3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20:1034-41
86. Pavlos R, Mallal S, Phillips E. 2012. HLA and pharmacogenetics of drug hypersensitivity. Pharmacoge-nomics 13:1285-306
87. Perez-Andreu V, Teruel R, Corral J, Roldan V, Garcia-Barbera N, et al. 2012. miR-133a regulates vitamin K 2, 3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle. Mol. Med. 18:1466-72
88. Pirmohamed M. 2010. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin. Pharmacol. Ther. 88:862-66
89. Pirmohamed M. 2011. Pharmacogenetics: past, present and future. Drug Discov. Today 16:852-61
90. Pirmohamed M. 2012. Genetics and the potential for predictive tests in adverse drug reactions. Chem. Immunol. Allergy 97:18-31
91. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D. 2011. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 89:784-85
92. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, et al. 2013. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369:2294-303
93. Pirmohamed M, Hughes DA. 2013. Pharmacogenetic tests: the need for a level playing field. Nat. Rev. Drug Discov. 12:3-4
94. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19
95. Poste G. 2011. Bring on the biomarkers. Nature 469:156-57
96. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45:164-71
97. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, et al. 2013. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 95:216-27
98. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, et al. 2012. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92:87-95
99. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, et al. 2013. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 13:325-29
100. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-45
101. Rawlins M. 2008. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 372:2152-61
102. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. 2011. Clinical Pharmacogenet-ics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89:387-91
103. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, et al. 2014. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955-62
104. *5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46:1111-18
105. Salama AK, Flaherty KT. 2013. BRAF in melanoma: current strategies and future directions. Clin. Cancer Res. 19:4326-34
106. Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, et al. 2002. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12:429-36
107. SEARCH Collab. Group. 2008. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359:789-99
108. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, et al. 2009. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-57
109. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, et al. 2010. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42:711-14
110. Sorich MJ, Polasek TM, Wiese MD. 2013. Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin. Pharmacol. Ther. 94:376-82
111. Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends Mol. Med. 7:201-4
112. *02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29:667-73
113. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, et al. 2005. Thiopurine methyltransferase (TPMT ) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293:1485-89
114. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-αand ribavirin therapy. Nat. Genet. 41:1100-4
115. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon- αand ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-9
116. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, et al. 2013. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62:2261-73
117. *5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19:704-9
118. *1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51:926-30
119. Thiesen S, Conroy EJ, Bellis JR, Bracken LE, Mannix HL, et al. 2013. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children? A prospective observational cohort study of 6, 601 admissions. BMC Med. 11:237
120. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120-29
121. Urban TJ. 2013. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 14:345-48
122. Vatsis KP, Martell KJ, Weber WW. 1991. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. USA 88:6333-37
123. Vessell E, Penno M. 1984. A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites. Biochem. Soc. Trans. 12:74-78
124. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, et al. 2013. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar. J. 12:112
125. *5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54:1609-16
126. Wadelius M, Pirmohamed M. 2007. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7:99-111
127. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. 2010. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6:39-51
128. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. 2013. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14:23-34
129. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, et al. 2007. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6:904-16
130. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, et al. 2012. The Clinical Pharmacoge-nomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92:112-17
131. Winter JW, Gaffney D, Shapiro D, Spooner RJ, Marinaki AM, et al. 2007. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 25:1069-77
132. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. 2012. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92:757-65
133. Yip VL, Pirmohamed M. 2013. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs 13:151-62
134. *13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369:1620-28